ISRCTN39055704已完成不适用
Phase III project, randomised controlled trial of brief intervention for illicit drugs linked to the World Health Organization (WHO) alcohol, smoking and substance involvement screening test (ASSIST): multicentre study conducted in Australia, Brazil, India, Spain, Thailand and USA
World Health Organization (WHO)/The Department of Mental Health and Substance Abuse (MSD) (Switzerland)0 个研究点目标入组 1,047 人开始时间: 2005年2月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,047
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age 18 - 50 years
- •2. Member of main ethnic group in the population
- •3. Able to communicate in the national language
- •4. Willing for three month follow-up
- •5. Be able to be followed up three months later and give contact details of two to three other people
- •6. Have a fixed address and provide contact details of their home
排除标准
- •1. Any pending court session with possible incarceration within three months
- •2. Any severe intellectual disability or cognitive impairment
- •3. Severe behaviour disturbance or psychotic symptoms
- •4. Tendencies to violent or aggressive behaviour
- •5. Intoxicated or withdrawal from alcohol or drugs
- •6. Incarcerated or in the environment with no free movements in the last three months
研究者
相似试验
进行中（未招募）
不适用
A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancerCancer - Ovarian and primary peritonealOvarian CancerACTRN12614001311640niversity of Sydney524
已完成
不适用
A phase III open, randomised, controlled study to evaluate the safety and immunogenicity of a paediatric dose (0.25 ml) and the standard dose (0.5 ml) of Epaxal® with reference to comparator vaccine in healthy children and adolescents (12 months to 16 years of age inclusive), using a 0/6 month scheduleHepatitis A VirusInfections and InfestationsHepatitisISRCTN91009479Berna Biotech AG (Switzerland)360
进行中（未招募）
不适用
A phase III randomised, controlled study to assess in a double blind manner the lot-to-lot consistency of three consecutive production lots of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine and to evaluate the non-inferiority to Prevenar™ in a single blind design, when administered as a 3-dose primary immunization course before 6 months of age. - 10PN-PD-DIT-001EUCTR2005-003300-11-FIGlaxoSmithKline Biologicals1,600
进行中（未招募）
不适用
A phase IIIa open, randomised, controlled study to assess the safety, reactogenicity and immunogenicity induced by a booster dose of GlaxoSmithKline (GSK) Biologicals 10-valent pneumococcal conjugate vaccine when co-administered with GSK Biologicals’ measles-mumps-rubella-varicella vaccine (MMRV) vaccine in children during their second year of life, previously vaccinated in infancy in the primary study 10PN-PD-DIT-001 (105553) with GSK Biologicals 10-valent pneumococcal conjugate vaccine. - 10PN-PD-DIT-022 BST: 001Booster vaccination against Streptococcus pneumoniae and active immunization against measles, mumps, rubella and varicella diseases in children during the second year of life.EUCTR2006-001934-42-FIGlaxoSmithKline Biologicals400
招募中
3 期
Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 Gastric Cancer patients (JCOG1907, MONA LISA study)clinical stage T1-4aN0-3 Gastric CancerJPRN-UMIN000039825Japan Clinical Oncology Group (JCOG)1,040